Advocacy materials

Effect of the Affordable Medicines Facility—malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data

Peer-reviewed | Kenya | Madagascar | Nigeria | Uganda | 2012

Tougher S. et al., The Lancet, Volume 380, Issue 9857, Pages 1916-1926, 1 December 2012, doi10.1016/S0140-6736(12)61732-2.

Oral Artemisinin Monotherapy (oral AMT) Products found in 2013 ACTwatch Outlet Surveys

Multi-country | Cambodia | DR Congo | Madagascar | Myanmar | Nigeria | Uganda | 2014

The table outlines all oral artemisinin monotherapy (oAMT) products found during 2013 ACTwatch surveys. Photos are included where available. Among 6 countries surveyed in 2013,  oral AMT was found to be available in the DRC, Cambodia, Myanmar, and Nigeria. No oral AMT was found in Madagascar or Uganda.

Providing Malaria Market Evidence through the ACTwatch Project

Multi-country | Cambodia | DR Congo | Nigeria | Uganda | 2014

This brochure describes how ACTwatch data can be used to monitor markets and provide evidence to guide policy-makers and programme managers.

Uganda 2013 Outlet Survey Results - Brief

Briefs | Uganda | 2014

This brief summarizes the results of the 2013 Uganda Outlet Survey. 

Uganda 2013 Outlet Survey Results - Presentation

Presentations | Uganda | 2014

This presentation was used during the Uganda National ACTwatch Outlet Survey Dissemination Meeting held on 2nd December 2014 in Kampala, Uganda. The presentation was given by Dr Megan Littrell, ACTwatch Principal Investigator, PSI. 

ACTwatch Outlet Surveys 2013‐2014 ORS and Zinc Availability Findings from 9 Countries

Multi-country | Benin | Cambodia | DR Congo | Kenya | Madagascar | Nigeria | Tanzania | Uganda | Zambia | 2015

ACTwatch antimalarial medicine outlet surveys were conducted in 2013 in the DRC (Kinshasa & Katanga provinces), Cambodia, Madagascar, Nigeria, and Uganda, and in 2014 in Benin, Kenya, Tanzania and Zambia. A representative sample of clusters was selected to provide national estimates (provincial estimates only in the DRC) as well as estimates in urban and rural areas in Benin, DRC, Kenya, Madagascar, Tanzania, Uganda and Zambia. Within selected clusters, a census of all outlets with the potential to sell or distribute antimalarials and/or provide malaria blood testing was completed. All enumerated outlets were administered a series of screening questions to assess eligibility of the ACTwatch outlet survey. Screened outlets were administered additional questions to assess availability of ORS and zinc. This document summarizes the findings from these ORS and zinc availability questions. 

Pages